Among all the patients with NSCLC, adding plasma NGS to tissue EGFR testing resulted in the detection of a therapeutically actionable mutation in 43.6% (23/54) cases, whereas if only tissue EGFR testing had been done, only 22.2% (12/54) cases would have had a clinical actionable finding. This evidence concerns the gene EGFR and non-small cell lung carcinoma.